Skip to main content

Utilization of Select Biological Products: A Descriptive Analysis

Basic Details
Date Posted
Status
Complete
Medical Product
Avastin (bevacizumab)
Epogen (epoetin alfa)
Inflectra (infliximab-dyyb)
Mvasi (bevacizumab-awwb)
Neupogen (filgrastim)
Remicade (infliximab)
Renflexis (infliximab-abda)
Retacrit (epoetin alfa-epbx)
Zarxio (filgrastim-sndz)
Zirabev (bevacizumab-bvzr)
Description

In this report, we examined utilization patterns of certain biological products (Avastin, Epogen, Inflectra, Mvasi, Neupogen, Remicade, Renflexis, Retacrit, Zarxio, Zirabev). The study period includes data from October 1, 2015 to June 30, 2021. The request was executed on Merative™ MarketScan® Research Databases on June 10, 2022.

Deliverables (1)
Sentinel Query Builder Report: Utilization of Select Biological Products: A Descriptive Analysis
Additional Details
FDA Center
CDER
Time Period
October 1, 2015 - June 30, 2021
Analysis Type
Descriptive
Population / Cohort
All individuals
Data Sources
Merative™ MarketScan® Research Databases
Related Links
Sentinel Drug Study: Zarxio (Filgrastim-sndz) & Signal Identification